Patrick Dillon

Patrick Dillon

Auto-generated profile, based on publicly available information

Patrick Dillon

Department of Internal Medicine, University of Virginia, Charlottesville, VA

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 May 2022 in Journal of Clinical Oncology
Verified
Journal Article
Open access
FBFrancois-Clement Bidard
Francois-Clement Bidard
VKVirginia G. Kaklamani
Virginia G. Kaklamani
PNPatrick Neven
Patrick Neven
GSGuillermo Streich
Guillermo Streich
Alberto J MonteroAlberto J Montero
Alberto J Montero
ABAditya Bardia
Aditya Bardia
PURPOSE: Patients with pretreated estrogen receptor (ER)–positive/human epidermal growth factor receptor 2 (HER2)–negative advanced breast cancer have poor prognosis. Elacestrant is a novel, oral selective ER degrader that demonstrated activity in early studies. METHODS: This randomized, open-label, phase III trial enrolled patients with ER-positive/HER2-negative advanced breast cancer who had one-two lines of endocrine therapy, required pretreatment with a cyclin-dependent kinase 4/6 inhibitor, and ≤ 1 chemotherapy. Patients were randomly assigned to elacestrant 400 mg orally once daily or standard-of-care (SOC) endocrine monotherapy. Primary end points were progression-free survival (PFS) by blinded independent central review in all patients and patients with detectable ESR1 mutations. RESULTS: Patients were randomly assigned to elacestrant (n = 239) or SOC (n = 238). ESR1 mutation was detected in 47.8% of patients, and 43.4% received two prior endocrine therapies. PFS was prolonged in all patients (hazard ratio = 0.70; 95% CI, 0.55 to 0.88; P = .002) and patients with ESR1 mutation (hazard ratio = 0.55; 95% CI, 0.39 to 0.77; P = .0005). Treatment-related grade 3/4 adverse events occurred in 7.2% receiving elacestrant and 3.1% receiving SOC. Treatment-related adverse events leading to treatment discontinuations were 3.4% in the elacestrant arm versus 0.9% in SOC. Nausea of any grade occurred in 35.0% receiving elacestrant and 18.8% receiving SOC (grade 3/4, 2.5% and 0.9%, respectively). CONCLUSION: Elacestrant is the first oral selective ER degrader demonstrating a significant PFS improvement versus SOC both in the overall population and in patients with ESR1 mutations with manageable safety in a phase III trial for patients with ER-positive/HER2-negative advanced breast cancer.

16 June 2015 in Head & Neck
Verified
Journal Article
Open access
PDPatrick M. Dillon
Patrick M. Dillon
SCSamhita Chakraborty
Samhita Chakraborty
CMChristopher A. Moskaluk
Christopher A. Moskaluk
PJPrashant J. Joshi
Prashant J. Joshi
CTChristopher Y. Thomas
Christopher Y. Thomas
Background: Adenoid cystic carcinoma (ACC) is a rare tumor of secretory glands. In this study, recent advances in molecular characterization and in therapeutics are reviewed.Methods: A search of articles in PubMed and of abstracts from national meetings was performed regarding ACC.Results: Recent genetic analyses found that recurrent chromosome 6:9 translocations in ACC generate an MYB:NFIB gene fusion resulting in overexpression of the MYB oncoprotein. Several other frequent mutations are recently published that may be relevant for drug development. Several trials of targeted drugs are reviewed. Some agents delay tumor progression, but tumor responses remain rare.Conclusion: ACCs have a characteristic chromosomal translocation, but also frequently pick up additional mutations. Clinical research is limited by the rarity and slow growth of ACC. Several ongoing trials are testing agents that inhibit fibroblast growth factor receptor signaling or other signaling pathways. Novel treatments based on the recently sequenced tumor genome are under development. © 2015 The Authors Head & Neck Published by Wiley Periodicals, Inc. 38: 620–627, 2016

28 March 2014 in JNCI: Journal of the National Cancer Institute
Verified
Journal Article
Open access
PDF file
HSHanna K. Sanoff
Hanna K. Sanoff
ADAllison M. Deal
Allison M. Deal
JKJanakiraman Krishnamurthy
Janakiraman Krishnamurthy
CTChad Torrice
Chad Torrice
PDPatrick Dillon
Patrick Dillon
HMHy Muss
Hy Muss
Background Senescent cells, which express p16 INK4a, accumulate with aging and contribute to age-related pathology. To understand whether cytotoxic agents promote molecular aging, we measured expression of p16 INK4a and other senescence markers in breast cancer patients treated with adjuvant chemotherapy. Methods Blood and clinical information were prospectively obtained from 33 women with stage I to III breast cancer at four time points: before anthracycline-based chemotherapy, immediately after anthracycline-based chemotherapy, 3 months after anthracycline-based chemotherapy, and 12 months after anthracycline-based chemotherapy. Expression of senescence markers p16 INK4a and ARF mRNA was determined using TaqMan quantitative reverse-transcription polymerase chain reaction in CD3+ T lymphocytes, telomere length was determined by Southern analysis, and senescence-associated cytokines were determined by enzyme-linked immunosorbent assay. Findings were independently assessed in a cross-sectional cohort of 176 breast cancer survivors enrolled a median of 3.4 years after treatment; 39% previously received chemotherapy. All statistical tests were two-sided. Results In prospectively analyzed patients, expression of p16 INK4a and ARF increased immediately after chemotherapy and remained elevated 12 months after treatment. Median increase in log2 p16 INK4a was 0.81 (interquartile range = 0.28–1.62; Wilcoxon signed-rank P < .001), or a 75% absolute increase in expression, equivalent to the increase observed over 14.7 years of chronological aging. ARF expression was comparably increased (P < .001). Increased expression of p16 INK4a and ARF was associated with dose-dense therapy and hematological toxicity. Expression of two senescence-associated cytokines (VEGFA and MCP1) was durably increased by adjuvant chemotherapy. Telomere length was not affected by chemotherapy. In a cross-sectional cohort, prior chemotherapy exposure was independently associated with a log2-increase in p16 INK4a expression of 0.57 (repeated measures model, P < .001), comparable with 10.4 years of chronological aging. Conclusions Adjuvant chemotherapy for breast cancer is gerontogenic, inducing cellular senescence in vivo, thereby accelerating molecular aging of hematopoietic tissues.

1 December 2014 in JAMA Dermatology
Verified
Journal Article
Open access
PDF file
NTNancy E. Thomas
Nancy E. Thomas
AKAnne Kricker
Anne Kricker
WWWeston T. Waxweiler
Weston T. Waxweiler
PDPatrick M. Dillon
Patrick M. Dillon
KBKlaus J. Busam
Klaus J. Busam
MGMelanoma (GEM) Study Group
Melanoma (GEM) Study Group
The American Cancer Society has estimated that 76 100 new invasive melanomas will be diagnosed and 9710 people will die of melanoma in 2014 in the United States.1 Despite newly available targeted and immunomodulatory agents,2-5 systemic therapies rarely lead to cures. Thus, early detection of primary melanomas followed by surgical excision remains critical for good outcomes. While recognition of all melanomas can be difficult, lack of brown or black color in amelanotic melanoma at the time of clinical diagnosis removes a defining characteristic for melanoma identification. Several studies indicate that amelanotic melanoma is associated with adverse survival because the tumors are more advanced at diagnosis; however, the majority of studies included only small numbers of amelanotic melanoma cases entered at single study sites and used a clinical, not pathologic, definition of amelanotic melanoma or lacked centralized pathologic review.

21 July 2010 in Aging Cell
Verified
Journal Article
Open access
PDF file
ZSZhangfa Song
Zhangfa Song
GFGuido Von Figura
Guido Von Figura
YLYan Liu
Yan Liu
JKJohann M. Kraus
Johann M. Kraus
CTChad Torrice
Chad Torrice
KRKarl Lenhard Rudolph
Karl Lenhard Rudolph
Summary: Cellular aging is characterized by telomere shortening, which can lead to uncapping of chromosome ends (telomere dysfunction) and activation of DNA damage responses. There is some evidence that DNA damage accumulates during human aging and that lifestyle factors contribute to the accumulation of DNA damage. Recent studies have identified a set of serum markers that are induced by telomere dysfunction and DNA damage, and these markers showed an increased expression in blood during human aging. Here, we investigated the influence of lifestyle factors (such as exercise, smoking, body mass) on the aging‐associated expression of serum markers of DNA damage (CRAMP, EF‐1α, stathmin, n‐acetyl‐glucosaminidase and chitinase) in comparison with other described markers of cellular aging (p16INK4a upregulation and telomere shortening) in human peripheral blood. The study shows that lifestyle factors have an age‐independent impact on the expression level of biomarkers of DNA damage. Smoking and increased body mass indices were associated with elevated levels of biomarkers of DNA damage independent of the age of the individuals. In contrast, exercise was associated with an age‐independent reduction in the expression of biomarkers of DNA damage in human blood. The expression of biomarkers of DNA damage correlated positively with p16INK4a expression and negatively with telomere length in peripheral blood T‐lymphocytes. Together, these data provide experimental evidence that both aging and lifestyle impact on the accumulation of DNA damage during human aging.

30 September 2012 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
PRPatrick J. Roberts
Patrick J. Roberts
JUJerry E. Usary
Jerry E. Usary
DDDavid B. Darr
David B. Darr
PDPatrick M. Dillon
Patrick M. Dillon
APAdam D. Pfefferle
Adam D. Pfefferle
NSNorman E. Sharpless
Norman E. Sharpless
Purpose: Anticancer drug development is inefficient, but genetically engineered murine models (GEMM) and orthotopic, syngeneic transplants (OST) of cancer may offer advantages to in vitro and xenograft systems. Experimental Design: We assessed the activity of 16 treatment regimens in a RAS-driven, Ink4a/Arf-deficient melanoma GEMM. In addition, we tested a subset of treatment regimens in three breast cancer models representing distinct breast cancer subtypes: claudin-low (T11 OST), basal-like (C3-TAg GEMM), and luminal B (MMTV-Neu GEMM). Results: Like human RAS-mutant melanoma, the melanoma GEMM was refractory to chemotherapy and single-agent small molecule therapies. Combined treatment with AZD6244 [mitogen-activated protein–extracellular signal-regulated kinase kinase (MEK) inhibitor] and BEZ235 [dual phosphoinositide-3 kinase (PI3K)/mammalian target of rapamycin (mTOR) inhibitor] was the only treatment regimen to exhibit significant antitumor activity, showed by marked tumor regression and improved survival. Given the surprising activity of the “AZD/BEZ” combination in the melanoma GEMM, we next tested this regimen in the “claudin-low” breast cancer model that shares gene expression features with melanoma. The AZD/BEZ regimen also exhibited significant activity in this model, leading us to testing in even more diverse GEMMs of basal-like and luminal breast cancer. The AZD/BEZ combination was highly active in these distinct breast cancer models, showing equal or greater efficacy compared with any other regimen tested in studies of over 700 tumor-bearing mice. This regimen even exhibited activity in lapatinib-resistant HER2+ tumors. Conclusion: These results show the use of credentialed murine models for large-scale efficacy testing of diverse anticancer regimens and predict that combinations of PI3K/mTOR and MEK inhibitors will show antitumor activity in a wide range of human malignancies. Clin Cancer Res; 18(19); 5290–303. ©2012 AACR.